FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).
Xiuning Le(The University of Texas MD Anderson Cancer Center), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Shirish M. Gadgeel(Chinese University of Hong Kong), David Planchard(Université Paris-Saclay), Jerry Y. Hsu, Hidetoshi Hayashi(Kindai University), Alexander I. Spira(Virginia Cancer Specialists), Yanqiu Zhao(Henan Cancer Hospital), Kiyotaka Yoh(National Cancer Center Hospital East), Satoru Kitazono(The Cancer Institute Hospital), Nichole Baio, Martin Förster, Jonathan W. Riess(University of California Davis Medical Center), Yong Jiang(The First People's Hospital of Changzhou), William Leung, Yan Yu(Shanghai University of Traditional Chinese Medicine), Bo Gao(Blacktown & Mount Druitt Hospital), Marcin Kowanetz, Ying Cheng(Wenzhou Medical University), Óscar Juan(Hospital Universitari i Politècnic La Fe)
Cited by 5
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k